Rewards for Cannabis Abstinence-study

Cannabis Use Disorder Clinical Trial

— RECAB  

Official title:

The Cost-effectiveness of Contingency Management Compared to Standard Cognitive Behavioral Treatment for Treating Cannabis Use Disorder in Youth: A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05836207
• Other study ID #: 10390012110082
• Status: Recruiting
• Phase: N/A
• Start date: November 21, 2023
• Est. completion date: January 2027

Study information

• Verified date: May 2024
• Source: Parnassia Addiction Research Centre
• Contact: Eva Garssen, MsC
• Phone: +3188 358 20 34
• Email: e.garssen[@]brijder.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate the (cost-)effectiveness of contingency management (CM) compared with Cognitive Behavioural Therapy (CBT) for the treatment of cannabis use disorder (CUD) in youth (16-22 years).

The main questions it aims to answer are:

• What is the efficacy of 12 weeks outpatient CM versus CBT in youths with a CUD, in terms of cannabis abstinence during the intervention period?

• What is the long-term efficacy of CM versus CBT at 6- and 12-months follow-up (FU)?

• What is the cost-effectiveness of CM versus CBT at 12-months FU from a societal perspective?

Study hypotheses are:

1. CM will result in more cannabis-abstinent days than CBT during the intervention; 2. CM is more effective and cost-effective than CBT at 12 months follow-up.

Eligible patients (n=154) will be randomly assigned to either 12 weeks of outpatient CM or CBT. Assessments are conducted by trained research-assistants at baseline, after 6, 12, 26 and 52 weeks, and twice-weekly during treatment and consist of questionnaires, a computer task and collection of urine samples. Primary endpoint is the number of biochemically verified cannabis abstinent days in the 12-week treatment period. Key secondary endpoint: Treatment response: 50% or more reduction in cannabis use days in the past 4 weeks, compared with baseline.

The primary outcome will be modelled in the intention-to-treat population in a (negative binomial) regression analysis with treatment group as independent variable and stratification variables as covariates.

Cost-effectiveness and cost-utility analysis (CEA; CUA) will be performed from a societal perspective. CEA: Treatment response is the central clinical endpoint for calculations of incremental costs per responder. CUA: Incremental costs per QALY (based on EuroQoL).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 154
• Est. completion date: January 2027
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 22 Years

Eligibility

Inclusion Criteria:

• Youths (16-22 years) seeking treatment for a primary CUD

• Regular cannabis use (=14 days) in past 4 weeks

• Intention to cease cannabis use during intervention

• Able and willing to attend the treatment center and submit urine samples under supervision twice-weekly

• Informed consent.

Exclusion Criteria:

• Health contra-indications (e.g., acute psychosis/suicidality)

• Insufficient Dutch language.

Related Conditions & MeSH terms

• Cannabis Use Disorder
• Marijuana Abuse

Intervention

Behavioral:
• Abstinence-focused Contingency Management (CM) - stand alone
Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
• Standard Outpatient Cognitive Behavioural Therapy (CBT)
CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist. Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence.

Locations

Country	Name	City	State
Netherlands	Antes Youz	Rotterdam
Netherlands	Brijder	the Hague
Netherlands	Novadic-Kentron	Vught

Sponsors (9)

Lead Sponsor	Collaborator
Parnassia Addiction Research Centre	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam University of Applied Sciences, Antes, Brijder Verslavingszorg, Het Zwarte Gat, Leiden University Medical Center, Novadic-Kentron, Trimbos

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cannabis-abstinent days (biochemically verified)	Number of biochemically verified cannabis-abstinent days during the 12-week intervention period	12 weeks
Secondary	long-term 'treatment response'	defined as 50% or more reduction in cannabis use days in the 4 weeks preceding week 12 (end-of-treatment), and week 26 and 52, compared with baseline.	52 weeks
Secondary	Incremental costs per treatment responder	Incremental cost-effectiveness ratio (ICER) per treatment responder (see above) will be determined based on the incremental costs and effects of CM compared with CBT.	52 weeks
Secondary	Incremental costs per QALY	Incremental costs per quality-adjusted life years (QALY) gains based on the The 5-level EQ-5D version (EQ-5D-5L)	52 weeks